SCHEMBL29310737

SCHEMBL29310737

O=C(O)/C=C\C(=O)NC1(C(=O)O)CCCCC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
HTT P42858 1/20 0.43
NPC1 O15118 1/20 0.43
ALDH1A1 P00352 3/20 0.39
POLB P06746 1/20 0.38
TSHR P16473 2/20 0.35
TP53 P04637 1/20 0.35
EGLN1 Q9GZT9 1/20 0.35
EGLN3 Q9H6Z9 1/20 0.35
HPGD P15428 1/20 0.34
LPAR2 Q9HBW0 2/20 0.34
LPAR1 Q92633 1/20 0.34
LMNA P02545 1/20 0.34
CYP1A2 P05177 1/20 0.32
LPAR3 Q9UBY5 1/20 0.32
FABP4 P15090 3/20 0.31
FABP5 Q01469 3/20 0.31
CYP2C19 P33261 1/20 0.31
TDP2 O95551 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29310734 0.94 GAA (0.41) GAASMN1; SMN2HTTNPC1ALDH1A1
SCHEMBL21082480 0.81 KDM4E (0.42) GAASMN1; SMN2HTTNPC1ALDH1A1
SCHEMBL10595642 0.78 ALDH1A1 (0.36) SMN1; SMN2HTTALDH1A1TSHRHPGD
SCHEMBL10593961 0.78 ALDH1A1 (0.36) SMN1; SMN2HTTALDH1A1TSHRHPGD
SCHEMBL1839193 0.78 MAPT (0.35) GAASMN1; SMN2HTTNPC1ALDH1A1
SCHEMBL1841005 0.78 MAPT (0.35) GAASMN1; SMN2HTTNPC1ALDH1A1
SCHEMBL1841006 0.78 MAPT (0.35) GAASMN1; SMN2HTTNPC1ALDH1A1
SCHEMBL1839195 0.78 MAPT (0.35) GAASMN1; SMN2HTTNPC1ALDH1A1
SCHEMBL21082414 0.77 POLB (0.38) GAASMN1; SMN2HTTNPC1ALDH1A1
SCHEMBL8762317 0.76 ALDH1A1 (0.36) ALDH1A1TSHRLMNACYP1A2FABP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240226320-A1 DRUG CONJUGATES WITH SELF-STABILIZING LINKERS HAVING IMPROVED PHYSIOCHEMICAL PROPERTIES SEAGEN INC (US) 2024-07-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240226320-A1 DRUG CONJUGATES WITH SELF-STABILIZING LINKERS HAVING IMPROVED PHYSIOCHEMICAL PROPERTIES CD44, CD47, UACA GAA 233/4885SMN1; SMN2 452/4885HTT 936/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.